Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
8,836
archived clinical trials in
Leukemia

Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated:  7/19/2016
Louis A. Weiss Memorial Hospital
mi
from
Chicago, IL
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated: 7/19/2016
Louis A. Weiss Memorial Hospital
mi
from
Chicago, IL
Click here to add this to my saved trials
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated:  7/19/2016
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated: 7/19/2016
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
Click here to add this to my saved trials
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated:  7/19/2016
Veterans Affairs Medical Center - Togus
mi
from
Togus, ME
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated: 7/19/2016
Veterans Affairs Medical Center - Togus
mi
from
Togus, ME
Click here to add this to my saved trials
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated:  7/19/2016
Marlene & Stewart Greenebaum Cancer Center, University of Maryland
mi
from
Baltimore, MD
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated: 7/19/2016
Marlene & Stewart Greenebaum Cancer Center, University of Maryland
mi
from
Baltimore, MD
Click here to add this to my saved trials
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated:  7/19/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated: 7/19/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated:  7/19/2016
University of Massachusetts Memorial Medical Center
mi
from
Worcester, MA
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated: 7/19/2016
University of Massachusetts Memorial Medical Center
mi
from
Worcester, MA
Click here to add this to my saved trials
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated:  7/19/2016
Veterans Affairs Medical Center - Minneapolis
mi
from
Minneapolis, MN
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated: 7/19/2016
Veterans Affairs Medical Center - Minneapolis
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated:  7/19/2016
Veterans Affairs Medical Center - Columbia (Truman Memorial)
mi
from
Columbia, MO
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated: 7/19/2016
Veterans Affairs Medical Center - Columbia (Truman Memorial)
mi
from
Columbia, MO
Click here to add this to my saved trials
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated:  7/19/2016
Ellis Fischel Cancer Center - Columbia
mi
from
Columbia, MO
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated: 7/19/2016
Ellis Fischel Cancer Center - Columbia
mi
from
Columbia, MO
Click here to add this to my saved trials
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated:  7/19/2016
Barnes Jewish Hospital
mi
from
Saint Louis, MO
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated: 7/19/2016
Barnes Jewish Hospital
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated:  7/19/2016
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated: 7/19/2016
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Click here to add this to my saved trials
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated:  7/19/2016
CCOP - Southern Nevada Cancer Research Foundation
mi
from
Las Vegas, NV
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated: 7/19/2016
CCOP - Southern Nevada Cancer Research Foundation
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated:  7/19/2016
Norris Cotton Cancer Center
mi
from
Lebanon, NH
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated: 7/19/2016
Norris Cotton Cancer Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated:  7/19/2016
Veterans Affairs Medical Center - Buffalo
mi
from
Buffalo, NY
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated: 7/19/2016
Veterans Affairs Medical Center - Buffalo
mi
from
Buffalo, NY
Click here to add this to my saved trials
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated:  7/19/2016
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated: 7/19/2016
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated:  7/19/2016
CCOP - North Shore University Hospital
mi
from
Manhasset, NY
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated: 7/19/2016
CCOP - North Shore University Hospital
mi
from
Manhasset, NY
Click here to add this to my saved trials
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated:  7/19/2016
North Shore University Hospital
mi
from
Manhasset, NY
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated: 7/19/2016
North Shore University Hospital
mi
from
Manhasset, NY
Click here to add this to my saved trials
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated:  7/19/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated: 7/19/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated:  7/19/2016
The New York Presbyterian Hospital - Cornell Campus
mi
from
New York, NY
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated: 7/19/2016
The New York Presbyterian Hospital - Cornell Campus
mi
from
New York, NY
Click here to add this to my saved trials
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated:  7/19/2016
Mount Sinai Medical Center, NY
mi
from
New York, NY
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated: 7/19/2016
Mount Sinai Medical Center, NY
mi
from
New York, NY
Click here to add this to my saved trials
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated:  7/19/2016
CCOP - Syracuse Hematology-Oncology Associates of Central New York, P.C.
mi
from
Syracuse, NY
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated: 7/19/2016
CCOP - Syracuse Hematology-Oncology Associates of Central New York, P.C.
mi
from
Syracuse, NY
Click here to add this to my saved trials
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated:  7/19/2016
State University of New York Upstate Medical University
mi
from
Syracuse, NY
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated: 7/19/2016
State University of New York Upstate Medical University
mi
from
Syracuse, NY
Click here to add this to my saved trials
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated:  7/19/2016
Veterans Affairs Medical Center - Syracuse
mi
from
Syracuse, NY
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated: 7/19/2016
Veterans Affairs Medical Center - Syracuse
mi
from
Syracuse, NY
Click here to add this to my saved trials
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated:  7/19/2016
Lineberger Comprehensive Cancer Center, UNC
mi
from
Chapel Hill, NC
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated: 7/19/2016
Lineberger Comprehensive Cancer Center, UNC
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated:  7/19/2016
Veterans Affairs Medical Center - Durham
mi
from
Durham, NC
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated: 7/19/2016
Veterans Affairs Medical Center - Durham
mi
from
Durham, NC
Click here to add this to my saved trials
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated:  7/19/2016
Duke Comprehensive Cancer Center
mi
from
Durham, NC
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated: 7/19/2016
Duke Comprehensive Cancer Center
mi
from
Durham, NC
Click here to add this to my saved trials
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated:  7/19/2016
CCOP - Southeast Cancer Control Consortium
mi
from
Winston-Salem, NC
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated: 7/19/2016
CCOP - Southeast Cancer Control Consortium
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated:  7/19/2016
Comprehensive Cancer Center of Wake Forest University Baptist Medical Center
mi
from
Winston-Salem, NC
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated: 7/19/2016
Comprehensive Cancer Center of Wake Forest University Baptist Medical Center
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated:  7/19/2016
Arthur G. James Cancer Hospital - Ohio State University
mi
from
Columbus, OH
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated: 7/19/2016
Arthur G. James Cancer Hospital - Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated:  7/19/2016
Rhode Island Hospital
mi
from
Providence, RI
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated: 7/19/2016
Rhode Island Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated:  7/19/2016
Medical University of South Carolina
mi
from
Charleston, SC
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated: 7/19/2016
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated:  7/19/2016
Veterans Affairs Medical Center - Memphis
mi
from
Memphis, TN
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated: 7/19/2016
Veterans Affairs Medical Center - Memphis
mi
from
Memphis, TN
Click here to add this to my saved trials
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated:  7/19/2016
University of Tennessee, Memphis Cancer Center
mi
from
Memphis, TN
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated: 7/19/2016
University of Tennessee, Memphis Cancer Center
mi
from
Memphis, TN
Click here to add this to my saved trials
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated:  7/19/2016
Vermont Cancer Center
mi
from
Burlington, VT
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated: 7/19/2016
Vermont Cancer Center
mi
from
Burlington, VT
Click here to add this to my saved trials
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated:  7/19/2016
Veterans Affairs Medical Center - White River Junction
mi
from
White River Junction, VT
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated: 7/19/2016
Veterans Affairs Medical Center - White River Junction
mi
from
White River Junction, VT
Click here to add this to my saved trials
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated:  7/19/2016
Veterans Affairs Medical Center - Richmond
mi
from
Richmond, VA
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated: 7/19/2016
Veterans Affairs Medical Center - Richmond
mi
from
Richmond, VA
Click here to add this to my saved trials
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated:  7/19/2016
MBCCOP - Massey Cancer Center
mi
from
Richmond, VA
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated: 7/19/2016
MBCCOP - Massey Cancer Center
mi
from
Richmond, VA
Click here to add this to my saved trials
A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene
A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene
Status: Enrolling
Updated:  8/2/2016
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene
A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene
Status: Enrolling
Updated: 8/2/2016
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene
A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene
Status: Enrolling
Updated:  8/2/2016
University of California San Francisco Medical Center-Parnassus
mi
from
San Francisco, CA
A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene
A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene
Status: Enrolling
Updated: 8/2/2016
University of California San Francisco Medical Center-Parnassus
mi
from
San Francisco, CA
Click here to add this to my saved trials
A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene
A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene
Status: Enrolling
Updated:  8/2/2016
Children's Hospital Colorado
mi
from
Aurora, CO
A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene
A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene
Status: Enrolling
Updated: 8/2/2016
Children's Hospital Colorado
mi
from
Aurora, CO
Click here to add this to my saved trials
A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene
A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene
Status: Enrolling
Updated:  8/2/2016
Emory Children's Healthcare of Atlanta
mi
from
Atlanta, GA
A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene
A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene
Status: Enrolling
Updated: 8/2/2016
Emory Children's Healthcare of Atlanta
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene
A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene
Status: Enrolling
Updated:  8/2/2016
Johns Hopkins University
mi
from
Baltimore, MD
A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene
A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene
Status: Enrolling
Updated: 8/2/2016
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene
A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene
Status: Enrolling
Updated:  8/2/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene
A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene
Status: Enrolling
Updated: 8/2/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene
A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene
Status: Enrolling
Updated:  8/2/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene
A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene
Status: Enrolling
Updated: 8/2/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene
A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene
Status: Enrolling
Updated:  8/2/2016
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene
A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene
Status: Enrolling
Updated: 8/2/2016
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene
A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene
Status: Enrolling
Updated:  8/2/2016
The Hospital for Sick Kids
mi
from
Toronto,
A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene
A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene
Status: Enrolling
Updated: 8/2/2016
The Hospital for Sick Kids
mi
from
Toronto,
Click here to add this to my saved trials
Phase 2 Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923)
An Open-Label, Randomized, Multicenter Phase 2 Trial of Dasatinib (SPRYCEL®) vs. Dasatinib Plus Smoothened Antagonist (BMS-833923) in the Treatment of Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia (CML).
Status: Enrolling
Updated:  8/8/2016
John Theurer Cancer Center
mi
from
Hackensack, NJ
Phase 2 Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923)
An Open-Label, Randomized, Multicenter Phase 2 Trial of Dasatinib (SPRYCEL®) vs. Dasatinib Plus Smoothened Antagonist (BMS-833923) in the Treatment of Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia (CML).
Status: Enrolling
Updated: 8/8/2016
John Theurer Cancer Center
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Phase 2 Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923)
An Open-Label, Randomized, Multicenter Phase 2 Trial of Dasatinib (SPRYCEL®) vs. Dasatinib Plus Smoothened Antagonist (BMS-833923) in the Treatment of Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia (CML).
Status: Enrolling
Updated:  8/8/2016
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Phase 2 Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923)
An Open-Label, Randomized, Multicenter Phase 2 Trial of Dasatinib (SPRYCEL®) vs. Dasatinib Plus Smoothened Antagonist (BMS-833923) in the Treatment of Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia (CML).
Status: Enrolling
Updated: 8/8/2016
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Click here to add this to my saved trials
Phase 2 Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923)
An Open-Label, Randomized, Multicenter Phase 2 Trial of Dasatinib (SPRYCEL®) vs. Dasatinib Plus Smoothened Antagonist (BMS-833923) in the Treatment of Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia (CML).
Status: Enrolling
Updated:  8/8/2016
Huntsman Cancer Institute
mi
from
Salt Lake City, UT
Phase 2 Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923)
An Open-Label, Randomized, Multicenter Phase 2 Trial of Dasatinib (SPRYCEL®) vs. Dasatinib Plus Smoothened Antagonist (BMS-833923) in the Treatment of Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia (CML).
Status: Enrolling
Updated: 8/8/2016
Huntsman Cancer Institute
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Phase 2 Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923)
An Open-Label, Randomized, Multicenter Phase 2 Trial of Dasatinib (SPRYCEL®) vs. Dasatinib Plus Smoothened Antagonist (BMS-833923) in the Treatment of Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia (CML).
Status: Enrolling
Updated:  8/8/2016
Local Institution
mi
from
San Miguel De Tucuman,
Phase 2 Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923)
An Open-Label, Randomized, Multicenter Phase 2 Trial of Dasatinib (SPRYCEL®) vs. Dasatinib Plus Smoothened Antagonist (BMS-833923) in the Treatment of Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia (CML).
Status: Enrolling
Updated: 8/8/2016
Local Institution
mi
from
San Miguel De Tucuman,
Click here to add this to my saved trials